(Alliance News) - Hutchmed (China) Ltd on Tuesday said it has completed patient enrolment for its clinical trial exploring potential treatment therapies for adults with primary immune thrombocytopenia in China.

Hutchmed is a Hong Kong-based commercial-stage, biopharmaceutical company.

The ESLIM-01 study, initiated in October 2021, is a phase III clinical trial designed to test the efficacy and safety of sovleplenib in treating adult patients with ITP.

Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase, also known as Syk.

Hutchmed on Tuesday said that the last patient was enrolled on December 31, bringing the number of people enrolled to a total of 188.

The company expects topline results from the ESLIM-01 trial in the second half of 2023, followed by submission of results for presentation at an appropriate medical congress.

If positive, Hutchmed said it would initiate plans to apply for marketing authorization of sovleplenib by the China National Medical Products Administration.

Hutchmed shares were trading 2.2% lower at 258.30 pence each in London on Tuesday morning.

By Holly Beveridge; Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.